Home
    • Plans Blog Contact
    Embecta Corp logo

    Embecta Corp

    EMBC
    Last price US$3.43
    Market cap US$192.2m
    12M price change -69.54%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    West Pharmaceutical Services IncWST Industry peer Hologic IncHOLX Industry peer HaemoneticsHAE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Embecta Corp Overview

    Industry: Medical Instruments & Supplies

    Sector: Healthcare

    Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing patient's diabetes Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Embecta Corp into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 05, 2026

    Quarterly result summary

    Revenue was $221.8M (-14.4% YoY); EPS was -$4.1 (reported).

    Revenue $221.8M -14.4% YoY
    EPS -$4.1 reported
    Operating income $35M -44% YoY
    Net income $40M +70% YoY

    What changed

    • Revenue -14.4% YoY to $221.8M; EPS reported to -$4.1.
    • Operating income -44% YoY to $35M.
    • Net income +70% YoY to $40M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 05, 2026 SEC filing 8-K May 05, 2026 SEC filing 10-Q Feb 05, 2026 SEC filing 8-K Feb 05, 2026 Earnings release Earnings release Feb 05, 2026 SEC filing 8-K Nov 25, 2025 SEC filing 10-K Nov 25, 2025 Earnings release Earnings release Nov 25, 2025 SEC filing 10-Q Aug 08, 2025 SEC filing 8-K Aug 08, 2025 Earnings release Earnings release Aug 08, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 1.00/5
    Embecta Corp earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Return on Equity

    Score 2.07/5
    Embecta Corp exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Embecta Corp EMBC US$192.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.86/5
    Embecta Corp commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Embecta Corp EMBC US$192.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Leverage

    Score 3.22/5
    Embecta Corp attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Embecta Corp EMBC US$192.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Embecta Corp logo

    Embecta Corp

    US$3.43

    US$17.01

    +395.9% vs price

    US$192.2m

    -0.15%

    -69.54%